vs
NCR Atleos Corp（NATL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
NCR Atleos Corp的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 7.2%，领先5.5%），Revvity同比增速更快（5.9% vs 4.0%），NCR Atleos Corp自由现金流更多（$194.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 4.9%）
NCR Atleos Corp 前身为NCR公司（National Cash Register），是全球知名的软件、咨询与技术企业，提供多元专业服务与电子产品，业务覆盖自助服务 kiosk、销售点终端、自动柜员机、支票处理系统、条码扫描器等商用软硬件的研发与生产，服务全球各行业客户的数字化运营需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NATL vs RVTY — 直观对比
营收规模更大
NATL
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出1.9%
4.0%
净利率更高
RVTY
高出5.5%
7.2%
自由现金流更多
NATL
多$32.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $83.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 13.5% | 14.5% |
| 净利率 | 7.2% | 12.7% |
| 营收同比 | 4.0% | 5.9% |
| 净利润同比 | 102.4% | 3.9% |
| 每股收益（稀释后） | $1.09 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATLRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $979.0M | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润NATLRVTY
| Q4 25 | $83.0M | $98.4M | ||
| Q3 25 | $26.0M | $46.7M | ||
| Q2 25 | $39.0M | $53.9M | ||
| Q1 25 | $14.0M | $42.2M | ||
| Q4 24 | $41.0M | $94.6M | ||
| Q3 24 | $21.0M | $94.4M | ||
| Q2 24 | $27.0M | $55.4M | ||
| Q1 24 | $-9.0M | $26.0M |
毛利率NATLRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率NATLRVTY
| Q4 25 | 13.5% | 14.5% | ||
| Q3 25 | 9.8% | 11.7% | ||
| Q2 25 | 10.8% | 12.6% | ||
| Q1 25 | 9.5% | 10.9% | ||
| Q4 24 | 13.4% | 16.3% | ||
| Q3 24 | 10.6% | 14.3% | ||
| Q2 24 | 9.8% | 12.4% | ||
| Q1 24 | 6.5% | 6.8% |
净利率NATLRVTY
| Q4 25 | 7.2% | 12.7% | ||
| Q3 25 | 2.3% | 6.7% | ||
| Q2 25 | 3.5% | 7.5% | ||
| Q1 25 | 1.4% | 6.4% | ||
| Q4 24 | 3.7% | 13.0% | ||
| Q3 24 | 2.0% | 13.8% | ||
| Q2 24 | 2.5% | 8.0% | ||
| Q1 24 | -0.9% | 4.0% |
每股收益（稀释后）NATLRVTY
| Q4 25 | $1.09 | $0.86 | ||
| Q3 25 | $0.34 | $0.40 | ||
| Q2 25 | $0.52 | $0.46 | ||
| Q1 25 | $0.19 | $0.35 | ||
| Q4 24 | $0.56 | $0.77 | ||
| Q3 24 | $0.28 | $0.77 | ||
| Q2 24 | $0.37 | $0.45 | ||
| Q1 24 | $-0.13 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $456.0M | $919.9M |
| 总债务越低越好 | $2.7B | — |
| 股东权益账面价值 | $403.0M | $7.3B |
| 总资产 | $5.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 6.63× | — |
8季度趋势，按日历期对齐
现金及短期投资NATLRVTY
| Q4 25 | $456.0M | $919.9M | ||
| Q3 25 | $412.0M | $931.4M | ||
| Q2 25 | $357.0M | $991.8M | ||
| Q1 25 | $352.0M | $1.1B | ||
| Q4 24 | $419.0M | $1.2B | ||
| Q3 24 | $395.0M | $1.2B | ||
| Q2 24 | $374.0M | $2.0B | ||
| Q1 24 | $343.0M | $1.7B |
总债务NATLRVTY
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NATLRVTY
| Q4 25 | $403.0M | $7.3B | ||
| Q3 25 | $330.0M | $7.4B | ||
| Q2 25 | $350.0M | $7.6B | ||
| Q1 25 | $275.0M | $7.6B | ||
| Q4 24 | $219.0M | $7.7B | ||
| Q3 24 | $264.0M | $7.9B | ||
| Q2 24 | $250.0M | $7.9B | ||
| Q1 24 | $283.0M | $7.8B |
总资产NATLRVTY
| Q4 25 | $5.7B | $12.2B | ||
| Q3 25 | $5.7B | $12.1B | ||
| Q2 25 | $5.8B | $12.4B | ||
| Q1 25 | $5.7B | $12.4B | ||
| Q4 24 | $5.5B | $12.4B | ||
| Q3 24 | $5.7B | $12.8B | ||
| Q2 24 | $5.8B | $13.4B | ||
| Q1 24 | $5.8B | $13.4B |
负债/权益比NATLRVTY
| Q4 25 | 6.63× | — | ||
| Q3 25 | 8.45× | — | ||
| Q2 25 | 8.05× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.05× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $231.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $194.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 16.8% | 21.0% |
| 资本支出强度资本支出/营收 | 3.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.78× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $239.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流NATLRVTY
| Q4 25 | $231.0M | $182.0M | ||
| Q3 25 | $25.0M | $138.5M | ||
| Q2 25 | $-23.0M | $134.3M | ||
| Q1 25 | $123.0M | $128.2M | ||
| Q4 24 | $80.0M | $174.2M | ||
| Q3 24 | $107.0M | $147.9M | ||
| Q2 24 | $9.0M | $158.6M | ||
| Q1 24 | $148.0M | $147.6M |
自由现金流NATLRVTY
| Q4 25 | $194.0M | $161.8M | ||
| Q3 25 | $-5.0M | $120.0M | ||
| Q2 25 | $-44.0M | $115.5M | ||
| Q1 25 | $94.0M | $112.2M | ||
| Q4 24 | $62.0M | $149.8M | ||
| Q3 24 | $85.0M | $125.6M | ||
| Q2 24 | $-14.0M | $136.6M | ||
| Q1 24 | $124.0M | $129.7M |
自由现金流率NATLRVTY
| Q4 25 | 16.8% | 21.0% | ||
| Q3 25 | -0.4% | 17.2% | ||
| Q2 25 | -4.0% | 16.0% | ||
| Q1 25 | 9.6% | 16.9% | ||
| Q4 24 | 5.6% | 20.5% | ||
| Q3 24 | 7.9% | 18.4% | ||
| Q2 24 | -1.3% | 19.7% | ||
| Q1 24 | 11.9% | 20.0% |
资本支出强度NATLRVTY
| Q4 25 | 3.2% | 2.6% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 3.0% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 2.3% | 2.7% |
现金转化率NATLRVTY
| Q4 25 | 2.78× | 1.85× | ||
| Q3 25 | 0.96× | 2.97× | ||
| Q2 25 | -0.59× | 2.49× | ||
| Q1 25 | 8.79× | 3.03× | ||
| Q4 24 | 1.95× | 1.84× | ||
| Q3 24 | 5.10× | 1.57× | ||
| Q2 24 | 0.33× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATL
| Services | $848.0M | 74% |
| APJ | $136.0M | 12% |
| Americas Excluding United States | $135.0M | 12% |
| TT | $44.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
